Bertram, Clinton C. - Resultats de la cerca - Dipòsit Digital de Documents de la UAB

Cerca col·leccions:

Ordena'ls per:	Mostrar els resultats:	Format de visualizació:

Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats

Articles	1 registres trobats

19 p, 1.8 MB

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors : 3-Year Follow-Up (SPIRIT-P2) / Orbai, Ana-Maria (Johns Hopkins University School of Medicine) ; Gratacós, Jordi (Universitat Autònoma de Barcelona. Departament de Medicina) ; Turkiewicz, Anthony (Rheumatology Associates Clinical Research Unit (Birmingham, Estats Units)) ; Hall, Stephen (Monash University) ; Dokoupilova, Eva (Masaryk University. Department of Pharmaceutical Technology, Faculty of Pharmacy) ; Combe, Bernard (CHU Montpellier and Montpellier University) ; Nash, Peter (Griffith University. School of Medicine) ; Gallo, Gaia (Eli Lilly and Company) ; Bertram, Clinton C. (Eli Lilly and Company) ; Gellett, Amanda M. (Eli Lilly and Company) ; Sprabery, Aubrey Trevelin (Eli Lilly and Company) ; Birt, Julie (Eli Lilly and Company) ; Macpherson, Lisa (Eli Lilly and Company) ; Geneus, Vladimir J. (Eli Lilly and Company) ; Constantin, Arnaud (Université Toulouse III)
Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A. The objective of this study was to assess the long-term efficacy and safety (to week 156) of ixekizumab in patients with active psoriatic arthritis and inadequate response or intolerance to one or two tumor necrosis factor inhibitors. [...]
2020 - DOI (Digital Object Identifier)

10.1007/s40744-020-00261-0
Rheumatology and Therapy, Vol. 8 (march 2021) , p. 199-217

Vegeu també: autors amb noms similars
1	Bertram, Christine

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.